FDA Designates MDMA As “Breakthrough Therapy” For Post-Traumatic Stress Disorder

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to methylenedioxymethamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD). The designation follows years of lobbying and laboratory research for the drug.

MDMA, which is the main ingredient found in ecstasy, has been found to significantly relieve symptoms of PTSD - such as trauma -  in clinical use trials. The Multidisciplinary Association for Psychedelic Studies (MAPS), which has fundraised for MDMA research for close to 30 years, stated that Breakthrough Therapy Designation indicates that the FDA considers MDMA as a drug that could be superior to other PTSD . . .